Merck and non-profit organisation International Vaccine Institute (IVI) based in Seoul, South Korea, are collaborating to develop a more robust and scalable vaccine manufacturing processes. Merck will provide funding and expertise in areas of clarification and purification under a new research agreement between the two.
Eli Lilly and Merck have announced their existing collaboration will be extended with the aim to evaluate the safety and efficacy of the combination of Lilly’s Alimta (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).
Merck Serono, the biopharma division of German drug giant Merck, and Sutro Biopharma have announced a new collaboration and license agreement to develop antibody drug conjugates (ADCs). The two organisations will work alongside each other, using Sutro’s cell-free protein synthesis platforms, to discover and develop multiple ADCs, antibodies linked to cytotoxic drugs for increased targeted
Advisors for the US regulatory body, the FDA, have given strong support for the approval of Merck & Co’s bloodthinner drug, vorapaxar. The US regulatory agency’s Cardiovascular and Renal Drugs Advisory Committee yesterday voted 10-1 in favour of vorapaxar being allowed onto the US market as an adjunctive treatment for cutting atherothrombotic events in patients
troche 500 Jobs” src=”http://img217.imageshack.us/img217/6978/merck.png” width=”156″ height=”52″ />Merck & Co have unveiled plans to cut around 8,500 jobs, in addition to previously-announced cuts of 7,500 roles, in an attempt to decrease costs and improve competitiveness. Merck are expecting to make $2.50 billion in yearly cost savings by the end of 2015 and the majority of this
Merck have suffered a hindrance this week with the withdrawal of their Marketing Authorization Application for ridaforolimus in Europe. The European Medicines Agency (EMA) was evaluating ridaforolimus as a possible maintenance treatment for patients with soft tissue sarcoma or primary malignant bone tumour. Merck have licensed the drug, an M-TOR inhibitor from Ariad Pharmaceuticals.
Merck & Co announced yesterday that they are relocating their worldwide headquarters from Whitehouse Station, New Jersey to their existing offices in Summit, New Jersey as part of their cost-cutting programme. The office in Summit, New Jersey currently contains research, manufacturing, animal health and consumer care operations and houses 1,800 employees. The organisation will shut
The UK’s National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance recommending Janssen Cilag’s Incivo (telaprevir), in combination with Roche’s peginterferon alfa and ribavirin, as an option for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease. The final draft guidance recommends the drug as an
Merck KGaA has announced that they have signed two agreements for collaboration of their Merck Serono division with Ono Pharmaceutical Co. Ltd., headquartered in Osaka, Japan, to strengthen their multiple sclerosis and cancer franchises. The initial agreement grants Merck Serono exclusive license rights for the development and commercialization of ONO-4641 outside of Japan, Korea and
According to new data published in the British Medical Journal, the cervical cancer vaccine, Gardasil, produced by Merck and Sanofi, may be more cost effective than its competitor GlaxoSmithKline’s Cervarix. However, the differential benefits of both vaccines remain unclear, say researchers from the Health Protection Agency. The study has been updated from the one previously
